Updated July 27, 2026
If you live in Kentucky and are looking into compounded GLP-1 medication for weight management, this page is meant to save you an afternoon of tab-hopping. It covers how telehealth access works in the Commonwealth, what Kentucky’s medical and pharmacy boards actually say about telehealth prescribing and GLP-1 compounding, what compounded semaglutide and tirzepatide cost from real providers serving the state, and a side-by-side comparison table with sources you can check yourself. Prices in the table come only from providers’ own public pages, checked on the date above.
One disclosure before anything else: this site is operated by Gentle Health, a telehealth provider of compounded GLP-1 medications, and Gentle Health appears in the comparison below on the same terms as everyone else.
How compounded GLP-1 access works in Kentucky
The short version: for most Kentuckians, access now runs through a screen rather than a waiting room.
Kentucky permits physicians licensed in the state to evaluate and treat patients through telehealth, which means a patient in Paducah or Pikeville can complete a medical visit without driving to Louisville or Lexington. At Gentle Health, the process looks like this. A patient completes an online health intake covering medical history, current medications, and health goals. That intake is reviewed by James Simmons, MD, who is licensed to practice in Kentucky (license 59884, state board record). Dr. Simmons evaluates whether treatment is medically appropriate for that specific patient. If it is, he writes a patient-specific prescription, which is filled by a licensed compounding pharmacy and shipped to the patient’s Kentucky address. Follow-up, dose adjustments, and side effect questions go back to Dr. Simmons, not to a rotating cast of strangers.
That single-physician structure matters more than it might seem. Kentucky’s rules, covered below, put real weight on the prescriber’s individualized judgment for compounded medications. A model where one named physician evaluates each patient and documents the reasoning is well suited to that framework.
For readers in the state’s two largest metros, we have city-specific guides at online weight management in Lexington and online weight management in Louisville. The process is identical statewide; those pages cover local context.
Kentucky rules worth knowing
Kentucky is not a state where compounded GLP-1s exist in a regulatory vacuum. Both the medical board and the pharmacy board have spoken, and it is worth knowing what they said.
Telehealth prescribing. Kentucky law addresses telehealth directly in KRS Chapter 311, which governs physicians. KRS 311.5975 requires a treating physician using telehealth to ensure the patient’s informed consent and to maintain confidentiality, and it authorizes the Kentucky Board of Medical Licensure to set practice standards, including standards that ensure proper evaluation and treatment before prescribing. The practical upshot, summarized in the Center for Connected Health Policy’s Kentucky profile, is that telehealth care in Kentucky is held to the same standard as in-person care: the physician must be licensed in Kentucky, must actually evaluate the patient, and must document that evaluation. A questionnaire that no physician meaningfully reviews does not meet that bar.
Pharmacy compounding. The Kentucky Board of Pharmacy has published specific guidance on GLP-1 compounding, and it is blunt. The Board’s GLP-1 Compounding Guidance (pharmacy.ky.gov) explains that federal law prohibits pharmacies from compounding drug products that are “essentially copies of a commercially available drug product,” and that Kentucky’s own regulation, 201 KAR 2:076, enforces the same prohibition at the state level. During the federal shortage of semaglutide and tirzepatide products, compounding was broadly permitted; the guidance walks through the FDA’s 2025 timeline under which that shortage-era enforcement discretion ended for both drugs.
What remains permissible is narrower and more patient-specific. Under Section 503A of the federal Food, Drug, and Cosmetic Act, a compounded drug is not an “essential copy” if a change is made for an identified individual patient and the prescriber has determined that the change will produce a significant difference for that patient. The Board’s guidance stresses that a prescription listing only a patient name and a formulation is not enough; the prescriber’s determination has to be real and documented, and a lower price by itself does not qualify as a clinical difference.
The Board followed up with a Compliance Alert dated November 14, 2025, which addresses 503B outsourcing facilities specifically. Because 503B facilities compound without patient-specific prescriptions, they cannot use the individualized clinical-difference exception at all; the alert concludes that 503B facilities “generally may not lawfully compound these drugs” now that both are off the FDA shortage list. Patient-specific compounding, where it happens, must run through a 503A pharmacy working from an individual prescription. The alert also points back to the Board’s May 22, 2024 Declaratory Opinion requiring Kentucky pharmacies to source compounds only from legally authorized facilities.
For a Kentucky patient, three practical takeaways:
- The physician evaluating you should be licensed in Kentucky, and the evaluation should be a real one.
- A compounded GLP-1 prescription in Kentucky should be patient-specific, with the prescriber documenting why a compounded formulation makes a clinically significant difference for you.
- Compounded medications are not FDA-approved products, and any provider who implies otherwise is misstating the law.
None of this is legal advice, and board positions can change. But as of this writing, this is the landscape a careful Kentucky patient, and a careful provider, is operating in.
Compounded semaglutide in Kentucky
Semaglutide is a GLP-1 receptor agonist: it mimics a hormone the body releases after eating, which slows stomach emptying and reduces appetite. Compounded semaglutide is a version of that active ingredient prepared by a licensed compounding pharmacy for an individual patient under a prescription, rather than purchased as a finished commercial product. Compounded medications are not FDA-approved, and the FDA does not review them for safety or effectiveness before they are dispensed; that is precisely why the prescriber’s evaluation and documentation carry the weight they do in Kentucky.
Gentle Health offers compounded semaglutide to Kentucky patients in two forms, both cash-pay with no insurance involved:
- Oral compounded semaglutide: $112 per month
- Injectable compounded semaglutide: $135 per month
Both include the evaluation and ongoing care from Dr. Simmons. The price does not step up as the dose changes. For a deeper look at forms, dosing cadence, and what the first months of treatment involve, see our dedicated guide to compounded semaglutide in Kentucky.
Compounded tirzepatide in Kentucky
Tirzepatide works on two hormone pathways rather than one: GLP-1 and GIP, a second gut hormone involved in metabolic regulation. Like compounded semaglutide, compounded tirzepatide is prepared per individual prescription by a licensed compounding pharmacy, and it is not an FDA-approved product. The same Kentucky pharmacy-board framework described above applies: patient-specific prescription, documented clinical rationale, 503A pharmacy.
Gentle Health offers injectable compounded tirzepatide to Kentucky patients at $169 per month, cash-pay, evaluation and follow-up with Dr. Simmons included, with no price increase at higher doses. If you are weighing the two medications, our guide to compounded tirzepatide in Kentucky goes into how the decision usually gets made; the honest answer is that it is a clinical judgment for the prescribing physician, made against your history rather than a marketing page.
Provider options in Kentucky: comparison table
Methodology: providers listed alphabetically; prices were taken only from each provider’s public website on 2026-07-27, and where a provider does not publish compounded GLP-1 pricing we write “See site” rather than guessing. Gentle Health operates this site and is listed on the same terms.
| Provider | Care model | Compounded semaglutide (cash/mo) | Compounded tirzepatide (cash/mo) | Serves Kentucky | Insurance | Source |
|---|---|---|---|---|---|---|
| Armstrong Telehealth | Telehealth practice (Pewee Valley, KY); $60 per visit plus medication cost | $100-200 listed (site does not specify compounded vs. brand) | $100-450 listed (site does not specify compounded vs. brand) | Yes (KY and WY) | Helps patients seek coverage where possible | armstrongtelehealth.com (verified 2026-07-27) |
| Bluegrass Telehealth | Telehealth clinic based in Lexington, KY; GLP-1 and non-GLP-1 programs | See site | See site | Yes | Advertises a Medicare GLP-1 Bridge Program; details on site | bluegrasstelehealth.com (verified 2026-07-27) |
| Gentle Health (operates this site) | Telehealth; evaluation and ongoing care by James Simmons, MD (KY license 59884) | $112 oral / $135 injectable | $169 | Yes | No; cash-pay only | gentle.health (verified 2026-07-27) |
| Kentucky Bariatric Institute | In-person clinics in Georgetown, Maysville, and Winchester, KY; medical and surgical programs | See site | See site | Yes (in-person) | Yes; insurance coordinators on staff | kentuckybariatricinstitute.com (verified 2026-07-27) |
| Trimi Health | Telehealth; 50-state clinician network | $99 (annual plan; monthly plans from $175) | $125 (annual plan; monthly plans from $235) | Yes | No; cash-pay, FSA/HSA eligible | trytrimi.com/state/kentucky (verified 2026-07-27) |
A few notes on reading this table honestly. Annual-plan pricing, like Trimi’s, is a real price but assumes a twelve-month commitment paid up front or financed; compare it against monthly pricing, not across pricing structures. Per-visit models, like Armstrong’s, can suit patients who want a local practice relationship and possible insurance help with medication costs. In-person programs, like Kentucky Bariatric Institute’s, serve a different need entirely, including surgical options that no telehealth provider offers. And “See site” means exactly that: the provider may well offer compounded GLP-1s at competitive prices, but we will not print a number their own public pages do not.
Frequently asked questions
Is compounded semaglutide legal in Kentucky?
Compounding is a legal, regulated practice, but Kentucky’s Board of Pharmacy has made clear that compounded semaglutide is permissible only in narrow circumstances now that the federal shortage has ended: a patient-specific prescription from a licensed prescriber who determines and documents that a formulation change produces a significant difference for that individual patient, filled by a 503A pharmacy. Compounded semaglutide is not an FDA-approved product. See the Board’s guidance linked in the rules section above.
Is compounded tirzepatide legal in Kentucky?
The same framework applies as for semaglutide: patient-specific prescription, documented clinical rationale, 503A pharmacy. The Board’s November 2025 compliance alert added that 503B outsourcing facilities, which compound without patient-specific prescriptions, generally may not lawfully compound tirzepatide at all now that it is off the FDA shortage list.
Do I need to see a doctor in person in Kentucky to get a GLP-1 prescription?
No. Kentucky permits physicians licensed in the state to evaluate patients and prescribe through telehealth, provided the evaluation meets the same standard of care as an in-person visit and the physician obtains informed consent under KRS 311.5975. At Gentle Health, that evaluation is performed by James Simmons, MD, licensed in Kentucky.
Why does a compounded GLP-1 prescription in Kentucky need extra documentation?
Because Kentucky’s pharmacy board follows the federal rule that a compounded drug may not be an “essential copy” of a commercially available product. The exception requires the prescriber to determine, for the identified patient, that a change in the compounded formulation produces a significant clinical difference, and to document that determination. A bare prescription with a name and a formulation is not sufficient, and price alone does not count as a clinical reason.
How much does compounded GLP-1 treatment cost in Kentucky?
Based on public pricing checked on July 27, 2026: Gentle Health charges $112 per month for oral compounded semaglutide, $135 for injectable compounded semaglutide, and $169 for compounded tirzepatide, all cash-pay. Trimi lists $99 and $125 per month on annual plans, with monthly plans from $175 and $235. Armstrong Telehealth lists medication ranges of roughly $100-450 per month plus $60 per visit. Other Kentucky providers do not publish compounded pricing; check their sites directly.
Does insurance cover compounded GLP-1s in Kentucky?
Generally no. Insurance plans that cover GLP-1 medications almost always cover the FDA-approved commercial products, not compounded versions. Most compounded GLP-1 care in Kentucky is cash-pay. Gentle Health is cash-pay only and does not bill insurance.
I live in a rural part of Kentucky. Does any of this work differently for me?
No. Telehealth access is the same statewide, and prescriptions ship to any Kentucky address. The evaluation, the prescription requirements, and the pricing are identical whether you are in Louisville, Lexington, Bowling Green, or a county with no clinic for forty miles. That is arguably the population telehealth serves best.
A note on brand names, since Kentucky’s pharmacy board documents mention them: semaglutide and tirzepatide are the active ingredients in several FDA-approved products, including Ozempic, Wegovy, Mounjaro, and Zepbound, which is why those names appear in the regulatory materials cited above. Gentle Health does not sell Ozempic, Wegovy, Mounjaro, or Zepbound. We offer compounded semaglutide and tirzepatide, which are different products. Gentle Health is not affiliated with, endorsed by, or connected to the manufacturers of those products, and nothing on this page should be read as comparing compounded medications to them.
Reviewed by James Simmons, MD
Last updated: August 3, 2026
Compounded medications are not FDA-approved. Treatment subject to medical evaluation.